Mazindol

from Wikipedia, the free encyclopedia
Structural formula
Mazindol structural formula
Mazindol enantiomers (1: 1 mixture)
General
Non-proprietary name Mazindol
other names

( RS ) -5- (4-chlorophenyl) -3,5-dihydro-2 H -imidazo [2,1- a ] isoindol-5-ol ( IUPAC )

Molecular formula C 16 H 13 ClN 2 O
External identifiers / databases
CAS number 22232-71-9
EC number 244-857-0
ECHA InfoCard 100.040.764
PubChem 4020
DrugBank DB00579
Wikidata Q255680
Drug information
ATC code

A08 AA05

Drug class

Anti-obesity

properties
Molar mass 284.74 g mol −1
Physical state

firmly

Melting point

202-203 ° C

solubility

10 g l −1 in DMSO

safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
06 - Toxic or very toxic

danger

H and P phrases H: 300-311-331
P: 261-264-280-301 + 310-311
Toxicological data

36.3 mg kg −1 ( LD 50 ,  rat ,  oral )

As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Mazindol is a tricyclic isoindole derivative and a drug from the group of psychostimulants . It is not related to the tricyclic antidepressants .

Mazindol has been out of trade in Germany since 1990.

Indications

Mazindol is used for the initial treatment of obesity . Therapeutically sensible doses are between 1 and 3 mg / day at breakfast. This therapy principle is now outdated. It was beyond his approval for the treatment of daytime sleepiness in narcolepsy used.

pharmacology

Pharmacodynamics

Mazindol has a similar effect to amphetamine but is not itself an amphetamine derivative. It inhibits v. a. the resumption of the messenger substance norepinephrine .

Pharmacokinetics

Mazindol develops its maximum effect (T max ) after 2 to 4 hours. The bioavailability is 50%. The half-life is 33 to 55 hours. It is excreted renally to 25% and biliary to 75% .

Side effects and interactions

  • Common (1% -10%): Angina pectoris .
  • Rare (<0.1%): pulmonary hypertension
  • Also: insomnia, dizziness, agitation, confusion, mydriasis, somnolence, apathy, convulsions, coma; Difficulty urinating, urinary retention, impotence; Dry mouth, sweating, thirst, chills; Stomach pressure, constipation, diarrhea, ileus; rarely palpitations, rash, muscle twitching, tachycardia, hypotension, arrhythmias, shock.

literature

  • Dykes, MHM: Evaluations of mazindol. In: Drug and Therap. Bull. 12 (1974), p. 1015.
  • Heikkila, RE: Pharmacological studies with several analogs of mazindol: correlation between effects on dopamine uptake and various in vivo responses. In: Eur. J. Pharmacol. (71 (2-3) / 1981), pp. 277-86.
  • Lean, ME: Ciclazindol: an oral agent with weight reducing properties and hypoglaecemic activity. In: Eur. J. Clin. Pharmacol. (25 (1) / 1983), pp. 41-45.

Individual evidence

  1. ↑ a b c d e Mazindol data sheet from Sigma-Aldrich , accessed on April 9, 2011 ( PDF ).
  2. ↑ Geert Mayer and a .: Narcolepsy: diagnosis and therapy . In: Deutsches Ärzteblatt , Heft 5, 2001, 98, pp. A249 – A254.